VALNEVA SE SP.ADS/2 (AYJ0) - Total Assets
Based on the latest financial reports, VALNEVA SE SP.ADS/2 (AYJ0) holds total assets worth €398.84 Million EUR (≈ $466.28 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
VALNEVA SE SP.ADS/2 - Total Assets Trend (2021–2025)
This chart illustrates how VALNEVA SE SP.ADS/2's total assets have evolved over time, based on quarterly financial data. Also see VALNEVA SE SP.ADS/2 stock valuation for the company's overall valuation and market capitalisation.
VALNEVA SE SP.ADS/2 - Asset Composition Analysis
Current Asset Composition (December 2025)
VALNEVA SE SP.ADS/2's total assets of €398.84 Million consist of 55.8% current assets and 44.2% non-current assets. Review AYJ0 total debt and obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 27.5% |
| Accounts Receivable | €27.73 Million | 7.0% |
| Inventory | €50.23 Million | 12.6% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €22.35 Million | 5.6% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how VALNEVA SE SP.ADS/2's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See VALNEVA SE SP.ADS/2 (AYJ0) stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: VALNEVA SE SP.ADS/2's current assets represent 55.8% of total assets in 2025, a decrease from 71.7% in 2021.
- Cash Position: Cash and equivalents constituted 27.5% of total assets in 2025, down from 42.4% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, an increase from 4.0% in 2021.
- Asset Diversification: The largest asset category is inventory at 12.6% of total assets.
VALNEVA SE SP.ADS/2 Competitors by Total Assets
Key competitors of VALNEVA SE SP.ADS/2 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH
|
USA | $1.21 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $1.07 Billion |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA
|
USA | $543.64 Million |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
|
Wecome Pharmaceutical Co Ltd
SHE:300878
|
China | CN¥1.49 Billion |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX
|
USA | $246.58 Million |
|
Relmada Therapeutics Inc
NASDAQ:RLMD
|
USA | $235.36 Million |
VALNEVA SE SP.ADS/2 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.38 | 2.61 | 2.78 |
| Quick Ratio | 1.85 | 2.14 | 2.25 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €129.21 Million | €184.43 Million | €194.46 Million |
VALNEVA SE SP.ADS/2 - Advanced Valuation Insights
This section examines the relationship between VALNEVA SE SP.ADS/2's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.13 |
| Latest Market Cap to Assets Ratio | 1.10 |
| Asset Growth Rate (YoY) | -20.2% |
| Total Assets | €398.84 Million |
| Market Capitalization | $438.08 Million USD |
Valuation Analysis
Above Book Valuation: The market values VALNEVA SE SP.ADS/2's assets above their book value (1.10x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: VALNEVA SE SP.ADS/2's assets decreased by 20.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for VALNEVA SE SP.ADS/2 (2021–2025)
The table below shows the annual total assets of VALNEVA SE SP.ADS/2 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €398.84 Million ≈ $466.28 Million |
-20.24% |
| 2024-12-31 | €500.03 Million ≈ $584.59 Million |
+8.69% |
| 2023-12-31 | €460.06 Million ≈ $537.86 Million |
-25.96% |
| 2022-12-31 | €621.34 Million ≈ $726.42 Million |
-23.98% |
| 2021-12-31 | €817.35 Million ≈ $955.57 Million |
-- |
About VALNEVA SE SP.ADS/2
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile t… Read more